Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results
View original at globenewswire.comEupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc…
O que extraímos desta fonte
The claims Via News extracted from this document. We point to the source; we don't replace it.
Company expects to continue to access manufactured products from the U.S.
60% confidenceEP-104GI is a unique treatment approach for EoE, administered as an injection into the esophageal wall providing local delivery of drug
60% confidenceDiffusphere technology has the potential to achieve fewer adverse events through precision targeting and stable delivery versus traditional drug delivery methods
60% confidenceEupraxia anticipates multiple clinical readouts from the ongoing RESOLVE trial and the initiation of additional clinical programs in new indications
60% confidenceExisting cash reserves and proceeds from Offering and anticipated future exercise of in-the-money warrants will be sufficient to fund the Company into the second half of 2028
60% confidenceThe Company expects to continue to access manufactured products from the U.S.
60% confidence2025 was a pivotal year for Eupraxia with significant clinical milestones in EP-104GI development and strengthened balance sheet
60% confidence2025 was a pivotal year for Eupraxia with significant clinical milestones in EP-104GI development and strengthened balance sheet
60% confidenceThe precision of Eupraxia's Diffusphere technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect
60% confidenceCompany anticipates multiple clinical readouts from ongoing RESOLVE trial and initiation of additional clinical programs in new indications
60% confidenceDiffusphere technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, potentially achieving fewer adverse events through precision targeting
60% confidenceExisting cash reserves and proceeds from the Offering and anticipated future exercise of in-the-money warrants will be sufficient to fund the Company into the second half of 2028
60% confidence